anti-VEGF

PreclinicalSmall molecule

Pfizer

anti-VEGF is one of 57 small molecule programs targeting Diabetic Macular Edema. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Diabetic Macular EdemaActive, not recruiting

Age-Related Macular DegenerationActive, not recruiting

Diabetic Macular EdemaPreclinical

Active, not recruiting

Competition

Competitive Landscape

237 competitors in Age-Related Macular Degeneration

#DrugCompanyPhaseTrials

Lucentis

Roche

Phase 3

64 2

Eylea

Regeneron

Phase 3

44 3

Vabysmo

Roche

Phase 3

13 4

Beovu

Novartis

Phase 3

10 5

Macugen

Pfizer

Phase 3

6 6

Avastin

BBio-Thera Solutions

Phase 3

18 7

Retaane

AAlcon Research

Phase 3

5 8

Kenalog

BBausch Health Americas, Inc.

Phase 3

2 9

Forzinity

SStealth BioTherapeutics Inc.

Phase 3

2 10

Luye Pharma Conbercept

CChengdu Kanghong Biotech Co., Ltd.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2029

Phase 2Recruiting

Oligometastases

NCT07062055

Q4 2029

Recruiting

Treatment

NCT06537908

Clinical

Trials by Indication[1]

Diabetic Macular Edema4 trials

Influence of Systemic Parameters in Diabetic Macular Edema - LIPSIA Study

Unknown status·UUniversity of Leipzig··NCT03762226·100 enrolled

A Retrospective Study of Anti-Vascular Endothelial Growth Factor (VEGF) Injections for Retinal Vein Occlusion or Diabetic Macular Edema

Completed· AbbVie logo

AbbVie··NCT01918371·323 enrolled

Diabetic Macular Edema Treated With Ozurdex (DMEO)

Completed·JJohns Hopkins University·Phase 2·NCT01951066·20 enrolled

Show 1 more trial

Efficacy Analysis of Anti-VEGF Drugs Combined With Micropulse Laser in the Treatment of Diabetic Macular Edema

Unknown status·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·N/A·NCT05759884·40 enrolled

Treatment3 trials

A Study on the Treatment Strategy of NVG Secondary to PDR

Completed·RRuijin Hospital·N/A·NCT05156021·39 enrolled

CLN-0046: Treatment of AMD Subjects With OTX-TKI

Completed·OOcular Therapeutix, Inc.·Phase 1·NCT03630315·29 enrolled

Anti-PD-1/PD-L1 Antibodies Plus Anti-VEGF Antibody Treatment in Patients With Advanced-Stage HCC

Recruiting·SShanghai Zhongshan Hospital··NCT06537908·50 enrolled

Age-Related Macular Degeneration2 trials

Anti-VEGF Therapy for Subfoveal Hemorrhage in Patients With Neovascular Age-Related Macular Degeneration

Terminated·JJohns Hopkins University··NCT03699618·1 enrolled

X-82 to Treat Age-related Macular Degeneration

Terminated·TTyrogenex·Phase 2·NCT02348359·157 enrolled

Gastrointestinal Tumors1 trial

Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors.

Terminated· Pfizer logo

Pfizer·Phase 1·NCT04171141·79 enrolled

Oligometastases1 trial

BRAVE Study: QL1706 + Bevacizumab + SBRT for BCLC-C HCC With PVTT or Oligometastases

Recruiting·SShandong Cancer Hospital and Institute·Phase 2·NCT07062055·46 enrolled

3 more indications

Neovascular AMD1 trial

Safety and Tolerability Study of Suprachoroidal Injection of CLS-AX Following Anti-VEGF Therapy in Neovascular AMD

Completed·CClearside Biomedical, Inc.·Phase 1/2·NCT04626128·27 enrolled

Endothelial Function1 trial

Effects of Anti-VEGF Targeted Drugs on Patients' Blood Pressure and Endothelial Function

Unknown status·PPeking University Third Hospital··NCT04962438·30 enrolled

Wet AMD1 trial

Seven-year Outcomes Following Intensive Anti-VEGF Therapy in Wet AMD

Completed·SSemmelweis University··NCT05678517·47 enrolled

Sources

References

[1]
ClinicalTrials.gov — 14 trial records for anti-VEGF. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — anti-VEGF compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for anti-VEGF. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Pfizer

anti-VEGF

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2029

Q4 2029

Trials by Indication[1]

Diabetic Macular Edema4 trials

Treatment3 trials

Age-Related Macular Degeneration2 trials

Gastrointestinal Tumors1 trial

Oligometastases1 trial

Neovascular AMD1 trial

Endothelial Function1 trial

Wet AMD1 trial

References

Drug Info

Quick Facts

Related News